文献速递胸部肿瘤

Selpercatinib治疗RET融合阳性非小细胞肺癌:LIBRETTO-001 I/II期试验最终安全性和疗效及总生存期

Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
PubMed 文献 · J Clin Oncol · 2025-02-21

LIBRETTO-001是一项I/II期单臂开放标签注册试验,评估Selpercatinib在RET融合阳性非小细胞肺癌中的最终疗效和安全性。经治患者ORR为62%,初治患者为83%,中位OS经治47.6个月、初治未达到。

要点

  • 经治患者ORR 62%,初治患者83%,中位缓解持续时间分别为31.6和20.3个月。
  • 经治患者中位PFS 26.2个月、中位OS 47.6个月,初治患者中位PFS 22.0个月、OS未达到。
  • 基线可测量中枢神经系统转移患者CNS-ORR达85%,安全性特征与既往报告一致。

核心结论

  • 经过大量额外随访,Selpercatinib在RET融合阳性非小细胞肺癌患者中持续显示持久缓解和颅内活性,安全性特征可控。

研究设计与样本

  • LIBRETTO-001(ClinicalTrials.gov注册号NCT03157128)是一项I/II期单臂开放标签注册试验,纳入RET依赖型癌症患者。
  • 本次报告RET融合阳性非小细胞肺癌患者最终疗效和安全性:既往接受过铂类化疗者N=247,初治者N=69,额外随访19个月。

主要发现

  • 经治患者ORR为62%,初治患者ORR为83%。
  • 经治患者中位DoR为31.6个月,初治患者为20.3个月(中位随访约38个月)。
  • 经治患者中位PFS为26.2个月,初治患者为22.0个月(中位随访约40个月)。
  • 经治患者中位OS为47.6个月,初治组未达到(中位随访约43个月);3年 landmark 估计经治患者57%存活,初治患者66%存活。
  • 基线有可测量中枢神经系统转移的26例患者中,CNS-ORR为85%,CNS-DoR为9.4个月,CNS-PFS为11.0个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety results of selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy (N = 247) or were treatment-naïve (N = 69). The objective response rate (ORR) was 62% for pretreated patients and 83% for treatment-naïve patients. Duration of response (DoR) was 31.6 months for pretreated and 20.3 months for treatment-naïve patients (median follow-up approximately 38 months). Median progression-free survival (PFS) was 26.2 months for pretreated and 22.0 months for treatment-naïve patients (median follow-up approximately 40 months). Median overall survival was 47.6 months in pretreated patients and was not reached in the treatment-naïve group (median follow-up approximately 43 months). At the 3-year landmark estimate, 57% of pretreated and 66% of treatment-naïve patients were alive. Among 26 patients with measurable CNS metastases at baseline, the CNS-ORR was 85% with a CNS-DoR of 9.4 months and CNS-PFS of 11.0 months. The safety profile of selpercatinib was consistent with previous reports. With substantial additional follow-up, selpercatinib continued to show durable responses and intracranial activity, with a manageable safety profile in patients with RET fusion-positive NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gautschi O, Park K, Solomon BJ, et al. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2025. PMID: 39983053. doi:10.1200/JCO-24-02076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。